Monkeypox (Mpox)
2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
Bavarian NordicJynneos
Bavarian NordicMVA-BN
Clinical Trials (2)
Total enrollment: 1,204 patients across 2 trials
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Start: Oct 2025Est. completion: Oct 2026744 patients
Phase 2Recruiting
Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
Start: Oct 2024Est. completion: May 2026460 patients
Phase 2Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 1,204 patients
1 companies competing in this space